Clinical Trials register - Search for Non-Hodgkin's Lymphoma

587 result(s) found for: Non-Hodgkin's Lymphoma. Displaying page 12 of 30.

EudraCT Number: 2006-002658-31

Sponsor Protocol Number: 71/2006/U/Sper

Start Date*: 2006-06-08

Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI

Full Title: OPEN LABEL, PHASE II PILOT STUDY OF STI571 IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA PTCL REFRACTORY, RESISTANT OR NOT AMENABLE TO CONVENTIONAL THERAPY.

Medical condition: PERIPHERAL T-CELL LYMPHOMA PTCL EXPRESSING PDGFRA

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10025310	Lymphoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2020-001021-31

Sponsor Protocol Number: GO41944

Start Date*: 2021-01-22

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN VERSUS RITUXIMAB IN COMBINATION WITH GEMCITA...

Medical condition: Relapsed or refractory diffuse large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2010-019832-11	Sponsor Protocol Number: EMI114238	Start Date*: 2010-07-13
Sponsor Name:GlaxoSmithKline Research and Development Ltd
Full Title: An open-label study to evaluate the utility of the apoptosis imaging biomarker [18F]ML-10 to assess the response to chemotherapy in patients with non Hodgkin's lymphoma.
Medical condition: Non Hodgkin’s lymphoma
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (Prematurely Ended)
Trial results: View results

EudraCT Number: 2008-000498-40

Sponsor Protocol Number: CRAD001N2301

Start Date*: 2009-06-08

Sponsor Name:Novartis Pharma Services AG

Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching pla...

Medical condition: Diffuse Large B-Cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) HU (Completed) SK (Completed) AT (Completed) IT (Completed) DE (Completed) GR (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2011-000033-36

Sponsor Protocol Number: LYMRIT-37-01

Start Date*: 2012-10-18

Sponsor Name:Nordic Nanovector ASA

Full Title: A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.

Medical condition: Non-Hodgkin B-cell lymphoma Part A: Relapsed indolent Non-Hodgkin B-cell lymphoma Part B: Relapsed follicular lymphoma Part C: Relapsed indolent Non-Hodgkin B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	22.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029547	Non-Hodgkin's lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) FR (Prematurely Ended) ES (Prematurely Ended) HR (Completed) HU (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed) DE (Completed) NL (Completed) BE (Completed)

Trial results: View results

EudraCT Number: 2021-006475-42

Sponsor Protocol Number: ICP-CL-00107

Start Date*: 2022-06-15

Sponsor Name:InnoCare Pharma Inc.

Full Title: A Phase I/II, Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies

Medical condition: B-cell malignancies, including only patients with Grades 1-3a FL, MZL, MCL, and CLL/SLL

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults

Gender: Male, Female

Trial protocol: PL (Completed)

Trial results: (No results available)

EudraCT Number: 2021-006556-14

Sponsor Protocol Number: RHCART1A

Start Date*: 2022-07-08

Sponsor Name:Rigshospitalet

Full Title: CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19-positive ALL and NHL (DAN-CART 1901)

Medical condition: Acute Lymphoblastic Leukemia and B-cell Non Hodgkin Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066109	Precursor B-lymphoblastic leukemia acute	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012855	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10060669	B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma	LLT
	20.0	100000004851	10036524	Precursor B-lymphoblastic lymphomas	HLT
	20.0	100000004851	10026798	Mantle cell lymphomas	HLT
	20.0	100000004851	10020068	High grade B-cell lymphomas Burkitt-like lymphoma	HLT
	20.0	100000004851	10036711	Primary mediastinal large B-cell lymphomas	HLT
	24.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10085128	Follicular lymphoma	PT

Population Age: Infants and toddlers, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-003560-31

Sponsor Protocol Number: UKM18_0021

Start Date*: 2020-01-29

Sponsor Name:Universitätsklinikum Münster

Full Title: A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)

Medical condition: diffuse large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2007-007056-33

Sponsor Protocol Number: FL2008 RCHOPGM

Start Date*: 2008-09-19

Sponsor Name:Goelams

Full Title: An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with RCHOP chemotherapy and Rituximab (MabThera®) ...

Medical condition: This study evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) and chemotherapy (CHOP) in patients with non bulky follicular non Hodgkin...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10025310	Lymphoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-016378-34

Sponsor Protocol Number: MI-CP204

Start Date*: 2010-06-30

Sponsor Name:MedImmune LLC

Full Title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

Medical condition: Relapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL)...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008976	Chronic lymphocytic leukemia	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067070	Follicular B-cell non-Hodgkin's lymphoma	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2006-003333-33

Sponsor Protocol Number: JJ0606

Start Date*: 2007-03-13

Sponsor Name:Cardiff and Vale NHS Trust

Full Title: A randomised controlled, open label, phase II pilot study comparing the toxicity of rituximab plus CHOP chemotherapy with rituximab plus CHOP chemotherapy and bortezomib in adults with newly diagno...

Medical condition: Diffuse large B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10012818	Diffuse large B-cell lymphoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2005-003479-19

Sponsor Protocol Number: UCL/05/134

Start Date*: 2006-02-02

Sponsor Name:University College London

Full Title: A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of Internat...

Medical condition: Diffuse large B-cell lymphoma Burkitt's lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	13.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006595	Burkitt's lymphoma	PT
	13.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2021-004555-16

Sponsor Protocol Number: M20-429

Start Date*: 2022-04-25

Sponsor Name:AbbVie Deutschland GmbH & Co. KG

Full Title: A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms

Medical condition: Relapsed/refractory Burkitt's or Burkitt-like lymphoma/leukemia, Diffuse large B-cell lymphoma , or other aggressive mature (CD20+) B-cell lymphomas

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004851	10006596	Burkitt's lymphomas	HLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003903	B-cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012822	Diffuse large B-cell lymphoma refractory	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-003735-16

Sponsor Protocol Number: KILT

Start Date*: 2021-06-16

Sponsor Name:LYSARC

Full Title: A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

Medical condition: Relapsed/refractory PTCL KIR3DL2-positive patients after at least one previous line of systemic based regimen of chemotherapy

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042980	T-cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10042979	T-cell lymphoma recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-001141-13

Sponsor Protocol Number: GO40516

Start Date*: 2020-02-21

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN...

Medical condition: B-cell non-Hodgkin lymphoma (NHL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10067070	Follicular B-cell non-Hodgkin's lymphoma	LLT
	20.0	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT
	21.0	100000004864	10012820	Diffuse large B-cell lymphoma NOS	LLT
	21.1	100000004864	10012856	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent	LLT
	21.1	100000004864	10023768	Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent	LLT
	21.1	100000004864	10012857	Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory	LLT
	21.1	100000004864	10023769	Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2012-005138-12

Sponsor Protocol Number: BRCAP-GELTAMO12

Start Date*: 2013-03-26

Sponsor Name:GELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea)

Full Title: Randomized phase II study of treatment with R-CHOP vs Bortezomib-R-CAP for young patients with poor IPI diffuse large B-cell lymphoma.

Medical condition: Diffuse large B cell lymphoma (DLBCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed)

Trial results: View results

EudraCT Number: 2007-005580-95

Sponsor Protocol Number: FL2008 RGM

Start Date*: 2008-09-19

Sponsor Name:Goelams

Full Title: An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follic...

Medical condition: This study evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with non bulky follicular non Hodgkin’s lymphoma with no prio...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10025310	Lymphoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-004034-42

Sponsor Protocol Number: GS-US-313-0125

Start Date*: 2013-10-31

Sponsor Name:Gilead Sciences, Inc.

Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indole...

Medical condition: Indolent Non-Hodgkin Lymphomas •Follicular lymphoma •Small lymphocytic lymphoma •Lymphoplasmacytic lymphoma (with or without Waldenström macroglobulinemia) •Marginal zone lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065856	Non-Hodgkin's lymphoma unspecified histology indolent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) GB (Completed) SE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Completed)

Trial results: View results

EudraCT Number: 2017-002605-35

Sponsor Protocol Number: HO151

Start Date*: 2018-08-28

Sponsor Name:HOVON Foundation

Full Title: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.

Medical condition: Diffuse large B-cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-003769-14

Sponsor Protocol Number: FIL_DLCL10

Start Date*: 2012-09-27

Sponsor Name:Fondazione Italiana Linfomi ONLUS

Full Title: R-CHOP-14 or R-CHOP-21 & consolidation PET–oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1)

Medical condition: Patient with diffuse large B cell lymphoma (DLBCL) with low risk profile according to age-adjusted IPI (0 with bulky or 1)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	100000004851	10012819	Diffuse large B-cell lymphomas	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Non-Hodgkin's Lymphoma